| Symbol | COGT |
|---|---|
| Name | COGENT BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 200 CAMBRIDGE PARK DRIVE,SUITE 2500, CAMBRIDGE, Massachusetts, 02140, United States |
| Telephone | +1 617 945-5576 |
| Fax | — |
| — | |
| Website | https://www.cogentbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001622229 |
| Description | Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Additional info from NASDAQ: |
2026-07-31 10:55
New Form SCHEDULE 13G - Cogent Biosciences, Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001323 <b>Size:</b> 7 KB
Read more
2026-07-06 20:30
Ferrante Karen Jean 🟢 acquired 627 shares (1 derivative) of Cogent Biosciences, Inc. (COGT) at $38.48 Transaction Date: Jul 01, 2026 | Filing ID: 296249
Read more
2026-06-30 12:00
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Read more
2026-06-12 12:01
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Read more
2026-06-12 12:00
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Read more
2026-06-11 20:30
Harwin Peter Evan 🟢 acquired 17.9K shares (1 derivative) of Cogent Biosciences, Inc. (COGT) at $31.98 Transaction Date: Jun 09, 2026 | Filing ID: 267665
Read more
2026-06-11 20:30
Ferrante Karen Jean 🟢 acquired 17.9K shares (1 derivative) of Cogent Biosciences, Inc. (COGT) at $31.98 Transaction Date: Jun 09, 2026 | Filing ID: 267663
Read more
2026-06-11 20:30
CAIN CHRISTOPHER W. 🟢 acquired 17.9K shares (1 derivative) of Cogent Biosciences, Inc. (COGT) at $31.98 Transaction Date: Jun 09, 2026 | Filing ID: 267662
Read more
2026-06-11 20:30
Shegog Todd 🟢 acquired 17.9K shares (1 derivative) of Cogent Biosciences, Inc. (COGT) at $31.98 Transaction Date: Jun 09, 2026 | Filing ID: 267670
Read more
2026-06-11 20:30
Morris Arlene 🟢 acquired 17.9K shares (1 derivative) of Cogent Biosciences, Inc. (COGT) at $31.98 Transaction Date: Jun 09, 2026 | Filing ID: 267667
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06915766 | Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocy… | — | Systemic Mastocytoses, Indolent | Available | — | — | ClinicalTrials.gov |
| NCT06948955 | Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patien… | — | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | Available | — | — | ClinicalTrials.gov |
| NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Soli… | Phase1 | PIK3CA Mutations | Recruiting | 2026-06-01 | 2029-08-01 | ClinicalTrials.gov |
| NCT07361562 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Sol… | Phase1 | Advanced Solid Tumor, Adult | Recruiting | 2025-12-30 | 2028-11-01 | ClinicalTrials.gov |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma a… | Phase1 | Intrahepatic Cholangiocarcinoma (Icc) | Active_Not_Recruiting | 2025-01-22 | 2027-06-01 | ClinicalTrials.gov |
| NCT06208748 | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Pat… | Phase2 | Gastrointestinal Stromal Tumors | Active_Not_Recruiting | 2024-08-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT05687942 | The REBUILD Trial: Closure of the Abdominal Wall | Na | Surgical Incision | Not_Yet_Recruiting | 2023-03-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo … | Phase2 | SSM | Active_Not_Recruiting | 2022-06-27 | 2030-04-01 | ClinicalTrials.gov |
| NCT05041530 | Abdominal Wall Closure After Laparotomy in Oncologic Surgery | Na | Laparotomy | Unknown | 2022-06-17 | 2023-06-01 | ClinicalTrials.gov |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subject… | Phase3 | Advanced Gastrointestinal Stromal Tumors | Recruiting | 2022-04-14 | 2030-01-01 | ClinicalTrials.gov |
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Phase2 | Advanced Systemic Mastocytosis (AdvSM) | Recruiting | 2021-11-09 | 2027-07-01 | ClinicalTrials.gov |
| NCT03680560 | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With H… | Phase1 | Solid Tumor | Terminated | 2019-03-13 | 2020-03-12 | ClinicalTrials.gov |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refr… | Phase1 | Multiple Myeloma | Terminated | 2018-02-22 | 2019-10-01 | ClinicalTrials.gov |
| NCT03189836 | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Ref… | Phase1 | Lymphoma | Terminated | 2017-10-04 | 2020-09-21 | ClinicalTrials.gov |
| NCT02840110 | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product | — | B Cell Lymphomas | Terminated | 2016-10-01 | 2021-02-23 | ClinicalTrials.gov |
| NCT02776813 | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | Phase1 | Lymphoma | Completed | 2016-08-01 | 2020-02-12 | ClinicalTrials.gov |
| NCT02401815 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With P… | Phase1 | Gastrointestinal Stromal Tumors | Completed | 2015-03-06 | 2020-05-11 | ClinicalTrials.gov |
| NCT00557921 | Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) | Phase3 | Acute Coronary Syndrome | Terminated | 2007-12-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00620802 | Pharmacodynamics of CGT 2168 Compared With Plavix® | Phase1 | Healthy | Completed | 2007-11-01 | 2008-05-01 | ClinicalTrials.gov |
Total clinical trials: 19
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| CGT6297 | Other | Phase PHASE1 | PIK3CA Mutations | RECRUITING | NCT07383506 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| Midazolam | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | RECRUITING | NCT05208047 |
| Sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | RECRUITING | NCT05208047 |
| CGT9486 | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | RECRUITING | NCT05208047 |
| CGT6297 | Other | Phase PHASE1 | PIK3CA Mutations | RECRUITING | NCT07383506 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| Placebo Tablets | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation B) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation A) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Midazolam | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 plus sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Placebo Tablets | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation B) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation A) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Midazolam | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 plus sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Placebo Tablets | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation B) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation A) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Midazolam | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 plus sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Placebo Tablets | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation B) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation A) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Midazolam | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 plus sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Placebo Tablets | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation B) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation A) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Midazolam | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 plus sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| Plavix | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00620802 |
| CGT-2168 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00620802 |
| Plavix | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00620802 |
| CGT-2168 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00620802 |
| Plavix (clopidogrel 75 mg) and aspirin | Other | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT00557921 |
| CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin | Other | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT00557921 |
| Plavix (clopidogrel 75 mg) and aspirin | Other | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT00557921 |
| CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin | Other | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT00557921 |
| SEA-BCMA | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03266692 |
| ACTR087 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03266692 |
| Trastuzumab | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03680560 |
| ACTR T Cell Product | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03680560 |
| rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT02776813 |
| ACTR087 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT02776813 |
| rituximab | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT03189836 |
| ACTR707 | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT03189836 |
| ACTR T Cell Product | Other | Preclinical | B Cell Lymphomas | TERMINATED | NCT02840110 |
| REBUILD Bioabsorbable | Other | Approved | Laparotomy | UNKNOWN | NCT05041530 |
| REBUILD | Other | Approved | Surgical Incision | NOT_YET_RECRUITING | NCT05687942 |
| Sunitinib | Other | Phase PHASE1 | Gastrointestinal Stromal Tumors | COMPLETED | NCT02401815 |
| Pexidartinib | Other | Phase PHASE1 | Gastrointestinal Stromal Tumors | COMPLETED | NCT02401815 |
| CGT9486 | Other | Phase PHASE1 | Gastrointestinal Stromal Tumors | COMPLETED | NCT02401815 |
| Sunitinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib | Other | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Bezuclastinib in combination with sunitinib | Other | Phase PHASE2 | Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT06208748 |
| Midazolam | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 plus sunitinib | Other | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT4255 | Other | Phase PHASE1 | Advanced Solid Tumor, Adult | RECRUITING | NCT07361562 |
| Placebo Tablets | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation B) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation A) | Other | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib | Other | Preclinical | Systemic Mastocytoses, Indolent | AVAILABLE | NCT06915766 |
| CGT6297 | Other | Phase PHASE1 | PIK3CA Mutations | NOT_YET_RECRUITING | NCT07383506 |
| CGT4859 | Other | Phase PHASE1 | Intrahepatic Cholangiocarcinoma (Icc) | ACTIVE_NOT_RECRUITING | NCT06777316 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| bezuclastinib | Other | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| CGT4859 | Other | Phase PHASE1 | Intrahepatic Cholangiocarcinoma (Icc) | ACTIVE_NOT_RECRUITING | NCT06777316 |
| Plavix (clopidogrel 75 mg) and aspirin | DRUG | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT00557921 |
| CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin | DRUG | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT00557921 |
| Plavix | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00620802 |
| CGT-2168 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00620802 |
| CGT6297 | DRUG | Phase PHASE1 | PIK3CA Mutations | NOT_YET_RECRUITING | NCT07383506 |
| CGT4255 | DRUG | Phase PHASE1 | Advanced Solid Tumor, Adult | RECRUITING | NCT07361562 |
| Bezuclastinib | DRUG | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| CGT4859 | DRUG | Phase PHASE1 | Intrahepatic Cholangiocarcinoma (Icc) | RECRUITING | NCT06777316 |
| Bezuclastinib in combination with sunitinib | DRUG | Phase PHASE2 | Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT06208748 |
| Midazolam | DRUG | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| CGT9486 plus sunitinib | DRUG | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
| Placebo Tablets | DRUG | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation B) | DRUG | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| Bezuclastinib Tablets (Formulation A) | DRUG | Phase PHASE2 | SSM | ACTIVE_NOT_RECRUITING | NCT05186753 |
| bezuclastinib | DRUG | Phase PHASE2 | Advanced Systemic Mastocytosis (AdvSM) | RECRUITING | NCT04996875 |
| Trastuzumab | DRUG | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03680560 |
| SEA-BCMA | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03266692 |
| ACTR707 | BIOLOGICAL | Phase PHASE1 | Lymphoma | TERMINATED | NCT03189836 |
| ACTR T Cell Product | BIOLOGICAL | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03680560 |
| rituximab | BIOLOGICAL | Phase PHASE1 | Lymphoma | TERMINATED | NCT03189836 |
| ACTR087 | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03266692 |
| Sunitinib | DRUG | Preclinical | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | NCT06948955 |
| Pexidartinib | DRUG | Phase PHASE1 | Gastrointestinal Stromal Tumors | COMPLETED | NCT02401815 |
| CGT9486 | DRUG | Phase PHASE3 | Advanced Gastrointestinal Stromal Tumors | ACTIVE_NOT_RECRUITING | NCT05208047 |
Total products: 153